| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 227.27▲ | 227.17▲ | 225.68▲ | 212.58▲ | 214.32▲ |
| MA10 | 227.11▲ | 225.62▲ | 220.99▲ | 209.49▲ | 206.01▲ |
| MA20 | 227.03▲ | 220.09▲ | 213.94▲ | 210.47▲ | 199.90▲ |
| MA50 | 224.93▲ | 212.44▲ | 210.04▲ | 201.67▲ | 191.41▲ |
| MA100 | 222.47▲ | 209.82▲ | 210.09▲ | 199.28▲ | 177.79▲ |
| MA200 | 214.72▲ | 210.56▲ | 207.11▲ | 192.50▲ | 157.62▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.024▼ | 0.319▲ | 1.897▲ | 0.723▲ | 2.315▲ |
| RSI | 59.523▲ | 66.783▲ | 71.220▲ | 72.165▲ | 67.396▲ |
| STOCH | 67.755 | 58.593 | 65.981 | 55.285 | 74.707 |
| WILL %R | -18.684▲ | -29.085 | -28.993 | -26.862 | -19.166▲ |
| CCI | 148.094▲ | 28.404 | 70.172 | 302.124▲ | 184.007▲ |
| ▲ PSAR&MOM | $DGX PSAR Switch Up + Momentum | Set Alert |
| ▲ RSI&MACD | $DGX MACD cross and RSI above 55 | Set Alert |
| ▲ RSI | $DGX RSI(14) Crossed Above 70 | Set Alert |
| ▲ MACD | $DGX MACD(12,26,9) Crossed Above Signal Line | Set Alert |
| ▲ GAP | $DGX Open Gap Up %5 | Set Alert |
| ▲ GAP | $DGX Open Gap Up %3 | Set Alert |
| ▲ GAP | $DGX Open Gap Up %2 | Set Alert |
| ▲ BREAK | $DGX Price Breaks 60 Days High | Set Alert |
| ▲ BREAK | $DGX Price Breaks 30 Days High | Set Alert |
| ▲ BREAK | $DGX Price Breaks 20 Days High | Set Alert |
| ▲ BREAK | $DGX Price Breaks 10 Days High | Set Alert |
| CDL | $DGX Doji Star Candlestick Pattern Detected | Set Alert |
| CDL | $DGX Doji Candlestick Pattern Detected | Set Alert |
|
Thursday, July 23, 2026 12:33 PM
"We now expect revenues to be between $11.95 billion and $12.05 billion... Reported EPS to be in a range of $9.97 to $10.17 and adjusted EPS in a range of $11.05 to $11.25." (Executive VP & CFO Samad) ...
|
|
Thursday, July 23, 2026 12:07 PM
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as ...
|
|
Thursday, July 23, 2026 05:30 AM
Quest Diagnostics Inc (DGX) reports robust financial performance with a 10% revenue increase, while navigating operational headwinds and strategic investments.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/07/26 | 228.09 | 237.78 | 220.00 | 227.90 | 3,758,294 |
| 22/07/26 | 207.13 | 212.30 | 205.4125 | 209.83 | 1,834,005 |
| 21/07/26 | 206.16 | 208.0099 | 204.10 | 206.84 | 691,774 |
| 20/07/26 | 208.61 | 211.00 | 205.61 | 207.66 | 822,787 |
| 17/07/26 | 210.95 | 214.40 | 209.41 | 210.68 | 955,390 |
| 16/07/26 | 201.00 | 209.56 | 201.00 | 209.41 | 991,572 |
| 15/07/26 | 204.68 | 206.41 | 201.12 | 201.77 | 1,193,064 |
| 14/07/26 | 202.80 | 208.52 | 201.13 | 206.00 | 865,780 |
| 13/07/26 | 207.48 | 210.76 | 207.01 | 207.35 | 568,808 |
| 10/07/26 | 208.25 | 209.86 | 207.0301 | 207.44 | 614,745 |
|
|
||||
|
|
||||
|
|